Prana Biotechnology Ltd. (PRAN)

1.34
0.03 2.46
NASDAQ : Health Technology
Prev Close 1.37
Open 1.33
Day Low/High 1.32 / 1.37
52 Wk Low/High 1.09 / 2.91
Volume 3.41K
Avg Volume 87.20K
Exchange NASDAQ
Shares Outstanding 8.95M
Market Cap 29.43M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Here's the Next Small-Cap Stock the Spec Money Will Chase

Here's the Next Small-Cap Stock the Spec Money Will Chase

Speculative money has returned to the markets with a vengeance in the small-cap arena.

Prana Biotechnology (PRAN) Stock Suddenly Surges

Prana Biotechnology (PRAN) Stock Suddenly Surges

Prana Biotechnology (PRAN) is surging today despite a lack of any significant news regarding the company, which develops drugs to treat neurodegenerative diseases.

A Beaten-Down Biotech Stock Poised to Perk Up

A Beaten-Down Biotech Stock Poised to Perk Up

The biotech sector is back in vogue today. Keep this beaten-down biotech stock on your radar.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries

Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Why Prana Biotechnology (PRAN) Stock Is Down Today

Why Prana Biotechnology (PRAN) Stock Is Down Today

Prana Biotechnology (PRAN) continued to decline on Tuesday after the company announced on Monday its phase II study of PBT2 in Alzheimer's disease failed. The experimental drug did not reach the study's main endpoint of a statistically significant reduction in beta amyloid plaque levels in patients' brains with prodromal or mild Alzheimer's. PBT2 also did not show an improvement in brain metabolic activity, cognition or function when compared to a placebo.

Prana Alzheimer's Study Fails

Prana Alzheimer's Study Fails

The experimental drug PBT2 failed to reduce beta amyloid plaque in the brain and couldn't improve cognition or function in Alzheimer's patients.

Off the Charts

Off the Charts

GM's brief break below the trend line triggers our short entry.

First Week Of November 22nd Options Trading For Prana Biotechnology (PRAN)

First Week Of November 22nd Options Trading For Prana Biotechnology (PRAN)

Investors in Prana Biotechnology Ltd saw new options begin trading this week, for the November 22nd expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Off the Charts

Off the Charts

GM is lagging the market, losing support of key short-term moving averages.

A Busy Calendar of March Biotech Events

A Busy Calendar of March Biotech Events

Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.

First Week of April 19th Options Trading For Prana Biotechnology (PRAN)

First Week of April 19th Options Trading For Prana Biotechnology (PRAN)

Investors in Prana Biotechnology Ltd saw new options begin trading this week, for the April 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PRAN options chain for the new April 19th contracts and identified one put and one call contract of particular interest.

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech Stock 'Hate' Mailbag: Readers Riot Over Galena, Prana

Biotech Stock 'Hate' Mailbag: Readers Riot Over Galena, Prana

I've received so much hate email and tweets over the past week, enough to fill a special edition of the Mailbag.

Independent Experts Cast Doubt on Prana HD Drug Efficacy Claims

Independent Experts Cast Doubt on Prana HD Drug Efficacy Claims

Read what doctors not involved in Prana's PBT2 study had to say about the results announced Tuesday.

Cheerleading Tweets From Prana's Harvard Scientist Propel Shares Higher

Cheerleading Tweets From Prana's Harvard Scientist Propel Shares Higher

In which I engage in a Twitter spat with a Harvard professor about Prana Bio's Huntington disease drug.

Prana Bio Huntington's Disease Drug Fails Key Efficacy Hurdles

Prana Bio Huntington's Disease Drug Fails Key Efficacy Hurdles

As expected, Prana focused on positive safety results from its Huntington's study of PB2, but the drug didn't improve cognition and motor function enough to matter.

Biotech Stock Mailbag: Prana Biotech

Biotech Stock Mailbag: Prana Biotech

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

First Week Of PRAN January 2014 Options Trading

First Week Of PRAN January 2014 Options Trading

Investors in Prana Biotechnology Ltd saw new options become available this week, for the January 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PRAN options chain for the new January 2014 contracts and identified one put and one call contract of particular interest.

4 Stocks Under $10 Moving Higher

4 Stocks Under $10 Moving Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Interesting PRAN Put And Call For May 2014

Interesting PRAN Put And Call For May 2014

Investors in Prana Biotechnology Ltd saw new options become available this week, for the May 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 232 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility.

TiVo: Small-Cap Winner

TiVo: Small-Cap Winner

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

American Medical, Global Crossing: Small-Cap Winners

American Medical, Global Crossing: Small-Cap Winners

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

Prana Biotech: Small-Cap Winner

Prana Biotech: Small-Cap Winner

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

10 Alzheimer's Disease Treatment Stocks

10 Alzheimer's Disease Treatment Stocks

Despite recent setbacks, investors are still searching for a company to unlock a treatment for Alzheimer's disease.

Reed's, Jones Soda: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Tuesday's session.

Prana Biotech, Radcom: Midday Volume Plays

Prana Biotech and Radcom were among several stocks trading near $5 moving on above-average volume during Monday's session.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

This week: Small-cap stocks garner reader attention.